DONGWHA PHARM.CO.,LTD
Financials
Valuation Metrics
DONGWHA PHARM.CO.,LTD's Market Cap is ₩1373B. At end of 2025 it was ₩1746B. Ranked #1033 of 2,436 in KR market (top 42%), #514 of 787 on KOSPI (top 65%), #123 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 53%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 137.28B KRW | KR#1,033/2,436 Sec#123/234 |
| Revenue | 501.33B KRW | KR#606/2,436 Sec#31/234 |
| Net Income | 14.30B KRW | KR#769/2,436 Sec#51/234 |
| Total Assets | 647.92B KRW | KR#630/2,436 Sec#35/234 |
| Net Assets | 409.65B KRW | KR#571/2,436 Sec#35/234 |
| Employees | 824 | KR#302/2,436 Sec#25/234 |
| Value | ||
| P/E | 9.60x | KR#690/2,436 Sec#36/234 |
| P/B | 0.34x | KR#397/2,436 Sec#12/234 |
| P/S | 0.27x | KR#543/2,436 Sec#9/234 |
| EV/EBITDA | 25.20x | KR#1,123/2,436 Sec#69/234 |
| FCF Yield | -27.30% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 3.49% | KR#1,171/2,436 Sec#84/234 |
| ROA | 2.21% | KR#1,101/2,436 Sec#87/234 |
| Op. Margin | 1.84% | KR#1,378/2,436 Sec#99/234 |
| Revenue Growth | 3.93% | KR#1,220/2,436 Sec#114/234 |
| Financial Health | ||
| Debt Ratio | 158.17% | KR#1,297/2,436 Sec#147/234 |
| Total Debt | 105.47B KRW | KR#693/2,436 Sec#40/234 |
| FCF | -37.48B KRW | KR#2,036/2,436 Sec#201/234 |
| Cash | 10.50B KRW | KR#1,648/2,436 Sec#130/234 |
| Current Ratio | 1.16x | KR#1,639/2,436 Sec#169/234 |
| Net Debt/EBITDA | 10.30x | KR#1,280/2,436 Sec#92/234 |
| Dividend | ||
| Div. Yield | 1.37% | KR#1,058/2,436 Sec#60/234 |
| Div. Growth | -63.89% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -24.03% | KR#1,401/2,436 Sec#121/234 |
| 1M Return | -3.06% | KR#1,217/2,436 Sec#119/234 |
| From 52W High | -34.99% | KR#566/2,436 Sec#40/234 |
| 1Y MDD | -35.00% | KR#344/2,436 Sec#22/234 |
| Trading | ||
| Volume | 122,248 shares | KR#822/2,436 Sec#81/234 |
| Foreign Own. | 2.73% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 668 KRW | KR#794/2,436 Sec#58/234 |
| BPS | 13,998 KRW | KR#702/2,436 Sec#49/234 |
Company Info
Established in 1897 and listed on the Stock Market in 1976, this pharmaceutical company acquired medical device manufacturer Medyssey in 2020 and Vietnamese pharmaceutical distribution chain TS Care in 2023. It specializes in manufacturing and selling pharmaceuticals, active pharmaceutical ingredients, quasi-drugs, and medical devices, also producing health functional foods. The company targets sustainable growth by addressing an aging society, improving economic standards, and developing biotech new drugs for intractable diseases. Dong Wha Pharmaceutical is headquartered in Jung-gu, Seoul Metropolitan City.